Ayala Pharmaceuticals, Inc. (AYLA)
NASDAQ: AYLA · IEX Real-Time Price · USD
1.15
+0.06 (5.49%)
Jul 6, 2022 9:30 AM EDT - Market open
Income Statement (Annual)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Revenue
|
3.51 | 3.71 | 2.33 | 0 |
| Revenue Growth (YoY)
|
-5.45% | 58.87% | - | - |
| Cost of Revenue
|
-3.51 | -3.71 | 1.29 | 0 |
| Gross Profit
|
7.01 | 7.42 | 1.05 | 0 |
| Selling, General & Admin
|
9.28 | 7.37 | 4.34 | 3.29 |
| Research & Development
|
29.94 | 22.41 | 14.42 | 5.74 |
| Operating Expenses
|
39.22 | 29.78 | 18.76 | 9.04 |
| Operating Income
|
-32.21 | -22.36 | -17.71 | -9.04 |
| Interest Expense / Income
|
0.26 | -0.06 | 0 | 0 |
| Other Expense / Income
|
7.01 | 7.42 | -0.23 | -0.45 |
| Pretax Income
|
-39.48 | -29.72 | -17.49 | -8.59 |
| Income Tax
|
0.78 | 0.43 | 0.31 | 0.29 |
| Net Income
|
-40.25 | -30.15 | -17.79 | -8.87 |
| Net Income Common
|
-40.25 | -30.15 | -17.79 | -8.87 |
| Shares Outstanding (Basic)
|
14 | 10 | 5 | 5 |
| Shares Outstanding (Diluted)
|
14 | 10 | 5 | - |
| Shares Change
|
46.02% | 98.02% | - | - |
| EPS (Basic)
|
-2.80 | -3.06 | -3.57 | -1.80 |
| EPS (Diluted)
|
-2.80 | -3.06 | -3.57 | - |
| Free Cash Flow Per Share
|
-2.66 | -2.80 | -3.27 | -1.34 |
| Gross Margin
|
200.00% | 200.00% | 44.94% | - |
| Operating Margin
|
-918.60% | -603.05% | -758.83% | - |
| Profit Margin
|
-1148.15% | -813.00% | -762.30% | - |
| Free Cash Flow Margin
|
-1094.15% | -743.96% | -697.51% | - |
| Effective Tax Rate
|
-1.97% | -1.43% | -1.75% | -3.33% |
| EBITDA
|
-39.05 | -29.6 | -17.34 | -8.54 |
| EBITDA Margin
|
-1113.81% | -798.14% | -742.76% | - |
| Depreciation & Amortization
|
0.17 | 0.18 | 0.15 | 0.05 |
| EBIT
|
-39.22 | -29.78 | -17.49 | -8.59 |
| EBIT Margin
|
-1118.60% | -803.05% | -749.19% | - |
Source: Financials are provided by
Nasdaq Data Link
and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).